MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

Neurology. 2006 Apr 25;66(8):1258-60. doi: 10.1212/01.wnl.0000208958.29600.87.

Abstract

Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Carboplatin / therapeutic use
  • Drug Therapy, Combination
  • Etoposide / therapeutic use
  • Female
  • Glioma / drug therapy
  • Glioma / pathology*
  • Glioma / therapy*
  • Humans
  • Irinotecan
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / therapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Etoposide
  • Irinotecan
  • Carboplatin
  • Camptothecin